VYGR
Voyager Therapeutics, Inc. NASDAQ Listed Nov 11, 2015$3.96
After hrs
$4.15
+0.00%
Mkt Cap $239.1M
52w Low $2.65
45.3% of range
52w High $5.55
50d MA $4.03
200d MA $4.04
P/E (TTM)
-1.8x
EV/EBITDA
-1.6x
P/B
1.1x
Debt/Equity
0.2x
ROE
-61.1%
P/FCF
-1.7x
RSI (14)
—
ATR (14)
—
Beta
1.38
50d MA
$4.03
200d MA
$4.04
Avg Volume
675.2K
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
75 Sidney Street · Lexington, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.54 | -0.46 | +14.8% | 4.11 | +0.0% | +21.7% | -3.0% | +0.4% | -8.4% | -3.1% | — |
| Nov 10, 2025 | AMC | -0.53 | -0.47 | +11.3% | 4.26 | -0.5% | +0.0% | -0.2% | -6.4% | -1.3% | +4.6% | — |
| Aug 6, 2025 | AMC | -0.48 | -0.57 | -18.8% | 3.40 | +0.0% | -5.3% | -2.5% | -1.9% | +10.1% | +7.7% | — |
| May 6, 2025 | AMC | -0.35 | -0.53 | -51.4% | 3.25 | -0.3% | +0.9% | +4.6% | -7.6% | +5.7% | -2.1% | — |
| Mar 11, 2025 | AMC | -0.35 | -0.59 | -68.6% | 3.97 | -4.3% | +2.3% | +0.2% | -4.2% | -0.3% | +0.0% | — |
| Nov 12, 2024 | AMC | -0.45 | -0.16 | +64.4% | 6.83 | +2.8% | -2.0% | -7.0% | -9.3% | -4.4% | -2.2% | — |
| Aug 6, 2024 | AMC | -0.38 | -0.18 | +52.6% | 8.19 | +4.2% | -14.0% | +3.1% | -4.7% | -4.2% | -0.5% | — |
| May 13, 2024 | AMC | -0.44 | -0.20 | +54.5% | 8.48 | +1.8% | +0.0% | +1.1% | +0.7% | -2.3% | +0.2% | — |
| Feb 28, 2024 | AMC | -0.29 | 1.25 | +531.0% | 8.97 | +10.8% | -7.2% | +13.5% | +2.1% | -5.6% | +1.4% | — |
| Nov 6, 2023 | AMC | -0.58 | -0.59 | -1.7% | 6.49 | -2.0% | +5.1% | -0.1% | -6.3% | -0.5% | -1.1% | — |
| Aug 3, 2023 | AMC | -0.59 | -0.51 | +13.6% | 9.31 | +0.9% | -4.9% | -1.9% | +2.4% | +1.8% | +0.9% | — |
| May 9, 2023 | AMC | 0.77 | 2.94 | +281.8% | 10.76 | +0.1% | -8.1% | -0.1% | +5.7% | -0.4% | +9.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.32 | $4.33 | +0.2% | -9.3% | -4.1% | -0.5% | +2.9% | +0.8% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.26 | $4.30 | +0.9% | -0.2% | -6.4% | -1.3% | +4.6% | +4.1% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.18 | $4.18 | +0.0% | +0.7% | +1.0% | +0.2% | +5.4% | -4.9% |
| Aug 7 | Wedbush | Maintains | Outperform → Outperform | — | $3.40 | $3.40 | +0.0% | -5.3% | -2.5% | -1.9% | +10.1% | +7.7% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.06 | $3.17 | +3.6% | -6.9% | +9.1% | -3.9% | +6.0% | +0.6% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.06 | $4.10 | +1.0% | +0.2% | -4.2% | -0.3% | +0.0% | +5.1% |
| Mar 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.06 | $4.10 | +1.0% | +0.2% | -4.2% | -0.3% | +0.0% | +5.1% |
| Mar 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.97 | $3.80 | -4.3% | +2.3% | +0.2% | -4.2% | -0.3% | +0.0% |
| Mar 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.97 | $3.80 | -4.3% | +2.3% | +0.2% | -4.2% | -0.3% | +0.0% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $3.97 | $3.80 | -4.3% | +2.3% | +0.2% | -4.2% | -0.3% | +0.0% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.08 | $4.13 | +1.2% | -4.2% | +1.3% | +4.8% | -0.2% | +2.9% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.62 | $5.60 | -0.4% | +0.2% | -0.5% | -1.4% | +1.6% | -2.9% |
| Nov 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.69 | $6.73 | +0.6% | -7.0% | -9.3% | -4.4% | -2.2% | +1.7% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.69 | $6.73 | +0.6% | -7.0% | -9.3% | -4.4% | -2.2% | +1.7% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.43 | $6.44 | +0.2% | +2.3% | +2.6% | +4.0% | +0.7% | -3.3% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.66 | $6.75 | +1.4% | +4.4% | -1.2% | -2.9% | +1.9% | +1.2% |
| Aug 7 | Wedbush | Maintains | Neutral → Neutral | — | $8.19 | $8.53 | +4.2% | -14.0% | +3.1% | -4.7% | -4.2% | -0.5% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.26 | $9.27 | +0.1% | -0.8% | -5.5% | -4.4% | -4.0% | +2.8% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.57 | $8.65 | +0.9% | +0.7% | -2.3% | +0.2% | -0.1% | -1.7% |
| May 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.48 | $8.52 | +0.5% | +1.1% | +0.7% | -2.3% | +0.2% | -0.1% |
| May 14 | Wedbush | Maintains | Neutral → Neutral | — | $8.48 | $8.63 | +1.8% | +0.0% | +1.1% | +0.7% | -2.3% | +0.2% |
| Jan 2 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $8.44 | $10.53 | +24.8% | +6.6% | +19.7% | +0.7% | -18.4% | +2.4% |
| Aug 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.85 | $8.77 | -1.0% | -1.9% | +2.4% | +1.8% | +0.9% | +2.3% |
| May 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $10.76 | $10.77 | +0.1% | -8.1% | -0.1% | +5.7% | -0.4% | +9.3% |
| May 10 | Truist | Maintains | Buy → Buy | — | $10.76 | $10.77 | +0.1% | -8.1% | -0.1% | +5.7% | -0.4% | +9.3% |
| Mar 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.91 | $8.25 | +4.3% | -4.9% | +4.7% | +5.3% | -3.3% | +2.4% |
| Nov 3 | Chardan Capital | Maintains | Neutral → Neutral | — | $3.89 | $3.89 | +0.0% | +2.6% | -5.3% | +0.5% | -3.9% | -1.1% |
| Oct 7 | Baird | Upgrade | Neutral → Outperform | — | $3.87 | $3.94 | +1.8% | -0.8% | +44.5% | -13.5% | -4.0% | -1.7% |
| Apr 19 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.56 | $4.56 | +0.0% | -2.0% | +4.5% | +2.6% | -1.9% | -0.6% |
| Feb 26 | Baird | Downgrade | Outperform → Neutral | — | $6.23 | $5.90 | -5.3% | -9.0% | +5.3% | -5.0% | -2.3% | +0.7% |
| Feb 3 | BTIG | Downgrade | Buy → Neutral | — | $8.00 | $7.00 | -12.5% | -6.4% | -0.3% | -0.3% | +3.4% | -2.1% |
| Feb 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.00 | $7.00 | -12.5% | -6.4% | -0.3% | -0.3% | +3.4% | -2.1% |
| Feb 3 | Wedbush | Downgrade | Outperform → Neutral | — | $8.00 | $7.00 | -12.5% | -6.4% | -0.3% | -0.3% | +3.4% | -2.1% |
| Nov 11 | Oppenheimer | Downgrade | Outperform → Perform | — | $8.60 | $8.71 | +1.3% | +2.9% | -2.5% | -0.9% | +2.2% | -0.3% |
| Nov 10 | Raymond James | Downgrade | Strong Buy → Outperform | — | $11.20 | $10.01 | -10.6% | -23.2% | +2.9% | -2.5% | -0.9% | +2.2% |
| Nov 10 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $11.20 | $10.01 | -10.6% | -23.2% | +2.9% | -2.5% | -0.9% | +2.2% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.33 | $10.83 | -4.4% | -8.6% | +4.4% | +1.7% | +1.8% | -0.1% |
| Apr 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.25 | $9.72 | -5.2% | -6.2% | -0.3% | +6.5% | +2.1% | +0.8% |
| Mar 30 | Nomura | Maintains | Buy → Buy | — | $9.05 | $9.11 | +0.7% | -3.3% | +4.6% | -12.0% | +8.1% | -6.6% |
| Mar 19 | Benchmark | Maintains | Buy → Buy | — | $7.16 | $7.26 | +1.4% | +5.6% | -8.7% | +4.6% | +18.1% | +8.1% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.58 | $12.31 | +6.3% | +4.3% | -3.6% | -5.8% | -6.9% | +6.5% |
| Mar 4 | Wedbush | Maintains | Outperform → Outperform | — | $11.58 | $12.31 | +6.3% | +4.3% | -3.6% | -5.8% | -6.9% | +6.5% |
| Mar 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.58 | $12.31 | +6.3% | +4.3% | -3.6% | -5.8% | -6.9% | +6.5% |
| Feb 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.66 | $13.10 | +3.5% | +7.6% | -4.8% | +0.0% | +1.9% | +2.3% |
| Oct 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $14.93 | $15.10 | +1.1% | +1.5% | -1.8% | +3.4% | -1.5% | +1.6% |
| Jul 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.67 | $26.02 | +1.4% | -0.7% | +0.6% | -3.5% | -3.2% | +2.5% |
| Mar 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.76 | $17.99 | +1.3% | -5.3% | +3.0% | -0.1% | +7.3% | -5.7% |
| Nov 15 | Raymond James | Upgrade | Outperform → Strong Buy | — | $11.25 | $12.43 | +10.5% | +8.3% | +2.2% | -6.9% | +0.2% | +2.2% |
| Nov 8 | Baird | Maintains | Outperform → Outperform | — | $13.99 | $11.20 | -19.9% | -12.0% | +0.0% | -6.6% | +2.5% | -4.7% |
| Jun 4 | H.C. Wainwright | Maintains | Buy → Buy | — | $20.41 | $22.27 | +9.1% | +3.6% | +2.4% | +3.9% | +0.0% | -0.6% |
No insider trades available.
8-K · 5.02
!!! Very High
Voyager Therapeutics, Inc. -- 8-K 5.02: Executive Change
Voyager Therapeutics replaced CFO Nathan Jorgensen while elevating Robin Swartz to COO and adding Amy Quinlan as director, signaling operational restructuring effective May 2026.
Apr 21
8-K
Voyager Therapeutics, Inc. -- 8-K Filing
Voyager Therapeutics expects 2026 to deliver pivotal data on tau-targeting Alzheimer's treatments, initiate clinical trials for IV-delivered gene therapies, and advance its nonviral delivery platform.
Mar 9
8-K
Voyager Therapeutics, Inc. -- 8-K Filing
Voyager Therapeutics disclosed SEC filing details regarding its emerging growth company status, which may affect regulatory reporting requirements and compliance obligations for investors.
Feb 12
Data updated apr 27, 2026 8:34am
· Source: massive.com